Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab and Cetuximab in Locally Advanced HNSCC
NCT05993858Phase 2Not yet recruiting
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC). Planned start Oct 2023; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05993858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993858.